CN1360899A - Dermatitis-treating bezoar medicine and its prepn - Google Patents
Dermatitis-treating bezoar medicine and its prepn Download PDFInfo
- Publication number
- CN1360899A CN1360899A CN 00126785 CN00126785A CN1360899A CN 1360899 A CN1360899 A CN 1360899A CN 00126785 CN00126785 CN 00126785 CN 00126785 A CN00126785 A CN 00126785A CN 1360899 A CN1360899 A CN 1360899A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- bezoar
- treating
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The dermatitis-treating bezoar medicine is prepared with seven kinds of Chinese medicinal materials and through crushing sweet wormwood, pine needle, dark plum and peppermint, percolating the medicine powder with 80-85% concentration ethanol solution to collect percolated liquid; adding glacial acetic acid; grinding borneol and bezoar into fine powder; mixing the fine powder with the said solution while stirring for full dissolution; and adding ethanol solution. The present invention has high curative rate, fast curative effect, and no toxic side effect.
Description
The present invention relates to a kind of treatment dermatosis, particularly treat external application preparation of neurodermatitis and preparation method thereof.
At present the Chinese and western drugs of treatment neurodermatitis is few, and curative effect is not as people's will, the medicine that doctor trained in Western medicine adopts, though some short term effects are arranged, relapse rate is very high, and late result is poor; As this sick antihistaminic class medicine that adopts for oral administration of external western medical treatment, as Cyproheptadine, chlorphenamine, this class of hismanal, external corticosteroid hormone class medicine, as carbamide ointment, fluocinonide ointment, dexamethasone ointment etc., bring into use curative effect obvious, but very fast recurrence, even knock-on deterioration phenomenon appears.For a long time with side effect such as atrophoderma wrinkle even anasarca, hypertension, diabetes, acne occurring.The domestic traditional Chinese medical science adopts that then heat-clearing and toxic substances removing for oral administration, dispelling wind for relieving itching, removing heat from blood are moisturized etc. Chinese medicine, but the many difficult through sick institutes of oral medicine, it is slow to take effect.And external used medicine mostly is Arsenicum sablimatum, Mylabris, Calomelas, Realgar, Venenum Bufonis, Semen Strychni, Flos Rhododendri Mollis, Herba Droserae Lunatae, five poisonous creatures: scorpion, viper, centipede, house lizard, toad wine and so on composition, and toxic and side effects is bigger, and how undesirable curative effect is.
Purpose of the present invention aims to provide a kind of topical agent dermatitis-treating bezoar medicine low than high curative rate, instant effect, relapse rate, the more satisfactory healing neurodermatitis that has no side effect that has.
Another object of the present invention provides the preparation method of this topical agent dermatitis-treating bezoar medicine.
The objective of the invention is to realize that by following manner medicine of the present invention is made by following component: Calculus Bovis, Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae, Borneolum Syntheticum, glacial acetic acid.By weight, wherein 0.1～1.5 part of Calculus Bovis, 40～60 parts of Herba Artemisiae Annuaes, 45～60 parts of Folium Pinis, 45～60 parts of Fructus Mumes, 45～70 parts of Herba Menthaes, 4～5.5 parts of Borneolum Syntheticums, 90～120 parts in glacial acetic acid.
Preferred weight (part) ratio range for preparing medicine of the present invention is: 0.5～1.2 part of Calculus Bovis, 50～55 parts of Herba Artemisiae Annuaes, 50～55 parts of Folium Pinis, 50～55 parts of Fructus Mumes, 50～60 parts of Herba Menthaes, 4.2～5.2 parts of Borneolum Syntheticums, 100～110 parts in glacial acetic acid.
Compound method of the present invention is: by said ratio (weight is in gram), get Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and be broken into coarse powder, the ethanol with 80～85% is solvent, carries out percolation by 3ml/min speed, collect the about 700～900ml of percolate, add glacial acetic acid acid and shake up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
Accompanying drawing is a process chart of the present invention.
Cow-bezoar of the present invention has heat-clearing and toxin-vanquishing, cooling blood, expelling wind, the kind characteristics of controlling all sore swollen toxins, is main ingredient of the present invention. The dark plum Main Ingredients and Appearance is that citric acid (19%) and malic acid (15 %) also contain butanedioic acid, carbohydrate, sitosterol, ceroidlike material and oleanolic acid sample material. Pharmacological research confirms that dark plum has antimycotic and anti-allergic effects. Pine needle has dispellings wind and arresting itching, the kind effect of controlling stubborn dermatitis scabies leprosy. Sweet wormwood, peppermint then have the effect of being apt to into liver and gall, removing heat from the liver, loose stagnated fire, walk to alter and borneol is refrigerant, and skin moistening and itch stopping is that hundred medicines are first, and dark plum and light-coloured vinegar all have acid convergence sore itching-relieving efficacies, and glacial acetic acid also has as molten coal, concocts all medicines. Because medicament of the present invention has the heat-clearing poison, changes irascibility, the profit skin, relieving itching, hold back the effect of stubborn dermatitis. The present invention has the cure rate height by clinical practice, instant effect, the characteristics that recurrence rate is low.
For showing medicament of the present invention to the result for the treatment of of neurodermatitis, the present invention is through 60 routine clinical observations, and selects two groups to use PIYANNING DINGs and each 30 example of fluocinolone acetonide ointment, as two groups of paired observations of B, C. A group 60 examples are for using medicament of the present invention. More than all make liver function and blood before and after the 120 routine patient treatments, routine urinalysis detects, every normal person includes treatment target in. Whether observe medicine after treatment finishes exerts an influence. 3 groups of sexes, age, the course of disease and medicine typing situations (seeing Table 1)
Sex, age, the course of disease and the medicine typing of table 1:3 group be (X+S) relatively
Annotate: Analysis of variance, 3 groups of sexes, age, the course of disease and medicine typing no significant differences.
| Group (n) | Sex (n) | Age | The course of disease | Medicine typing | |
| Liver depression deficiency of blood wind | |||||
| Fire (n) | Dry (n) | ||||
| A 60 | Man 32 | 36.4+16.4 | 5.6+6.8 | 12 | 20 |
| Woman 28 | 13 | 15 | |||
| B 30 | Man 15 | 38.1-17.2 | 6.7+10.1 | 8 | 7 |
| Woman 15 | 10 | 5 | |||
| C 30 | Man 18 | 41.3+17.9 | 6.7+7.8 | 8 | 10 |
| Woman 12 | 7 | 5 | |||
Observation of curative effect
Criterion of therapeutical effect is formulated with reference to " Chinese traditional medical diagnose standard ". Cure: skin undermines that symptom all disappears or residual pigmentation or pigment disappear; Take a turn for the better: attenuation before skin decreases, exfoliation reduces. Conscious itch alleviates or the skin damage disappears more than 30%; Invalid: the skin damage remains unchanged or disappears less than 30%. Subjective symptoms is without obvious improvement.
Skin lesion scoring method (1) skin lesion areameter point-score before controlling: area 100cm
2More than meter is 1 minute, 31～99cm
2More than meter is 2 minutes; 30cm
2Below meter is 3 minutes; No skin lesion meter 4 minutes.(2) skin crust thickness point system: plump meter 1 minute, thicker meter 2 minutes, thin meter 3 minutes, no crust meter 4 minutes.(3) pruritus degree point system: severe meter 1 minute, moderate meter 2 minutes was slightly counted 3 fens, no pruritus meter 4 minutes.
Control back skin lesion scoring method (1) skin lesion areameter point-score: the skin lesion area does not have to dwindle or enlarge to be counted 1 fen, and the skin lesion area dwindles more than 31% to be counted 3 fens.No skin lesion meter 4 minutes.(2) skin crust thickness point system: skin crust thickness no change or thicken the meter 1 minute, the more preceding attenuate of skin crust was counted 2 fens below 30%, the more preceding attenuate of skin crust was counted 3 fens more than 31%, no crust meter 4 minutes.(3) pruritus degree point system: pruritus does not alleviate or added restatement 1 minute, and pruritus alleviated meter below 50% 2 minutes, and pruritus alleviates more than 50% counted no pruritus meter 4 minutes 3 fens.
Observe in the 7th, 14,20 day 3 times of treatment.The recurrence situation then was respectively 3 months, 6 months and 1 year 3 months points carry out tracing study.
Therapeutic outcome (seeing Table 2,3,4)
The total mark difference compares (d+Sd branch) before and after the treatment of table 2:3 group erythra
| Group | ????n | Treated 7 days | Treated 14 days | Treated 20 days |
| ????A | ????60 | ??2.33+0.75 | ??4.30+1.12 | ??6.25+1.70 |
| ????B | ????30 | ??1.00+0.95 | ??1.67+1.58 | ??2.60+2.27 |
| ????C | ????30 | ??1.30+0.65 | ??2.63+1.00 | ??4.10+2.00 |
Annotate: treating 7 days F values is 35.23, and treating 14 days F values is 50.86, and treating 30 days F values is 38.38; More equal P＜0.01 between 3 months section groups.
Table 3:3 group therapeutic outcome is (example) relatively
| Group | Cure | Take a turn for the better | Do not heal | Add up to | Effective percentage (%) |
| ????A | ????40 | ????18 | ????2 | ????60 | ????96.7 |
| ????B | ????10 | ????10 | ????10 | ????30 | ????66.7 |
| ????C | ????15 | ????10 | ????5 | ????30 | ????83.3 |
Annotate: analyze X through Ridit
2=11.03, P＜0.005 shows 3 groups of effective percentage differences highly significants, with A group curative effect the best.
Table 4:3 group recurrence situation (example)
| Group | Recurrence in March | Recurrence in June | Recurrence in 1 year | Not recurrence | Add up to | Relapse rate (%) |
| ??A | ????1 | ????1 | ????2 | ????54 | ??58 | ????66.9 |
| ??B | ????2 | ????2 | ????2 | ????14 | ??20 | ????30.0 |
| ??C | ????10 | ????1 | ????1 | ????13 | ??25 | ????48.0 |
Annotate: analyze X through Ridit
2=10, P＜=0.005 shows 3 groups of relapse rate differences highly significants, is minimum with the A relapse rate wherein, and C group relapse rate in 3 months is the highest.
Three groups obvious adverse reaction all do not occur in the treatment.After the treatment, liver function and blood, routine urianlysis are all no abnormal.
Embodiment 1:
Take by weighing raw material (gram) Calculus Bovis 1.0, Herba Artemisiae Annuae 40, Folium Pini 55, Fructus Mume 45, Herba Menthae 50, Borneolum Syntheticum 4, glacial acetic acid 95, a certain amount of 75% ethanol by following proportioning.Get Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and be broken into coarse powder, the ethanol with 81% is solvent, carries out percolation by 3ml/min speed, collects the about 800ml of percolate, and the acid of adding glacial acetic acid shakes up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
Embodiment 2:
Take by weighing raw material (gram) Calculus Bovis 1.5, Herba Artemisiae Annuae 55, Folium Pini 50, Fructus Mume 50, Herba Menthae 60, Borneolum Syntheticum 5.5, glacial acetic acid 100, a certain amount of 75% ethanol by following proportioning.Get Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and be broken into coarse powder, the ethanol with 83% is solvent, carries out percolation by 3ml/min speed, collects the about 800ml of percolate, and the acid of adding glacial acetic acid shakes up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
Claims (4)
1, dermatitis-treating bezoar medicine; the medicine of its raw material is made by following component: Calculus Bovis, Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae, Borneolum Syntheticum, glacial acetic acid; by weight, wherein 0.1～1.5 part of Calculus Bovis, 40～60 parts of Herba Artemisiae Annuaes, 45～60 parts of Folium Pinis, 45～60 parts of Fructus Mumes, 45～70 parts of Herba Menthaes, 4～5.5 parts of Borneolum Syntheticums, 90～120 parts in glacial acetic acid.
2, according to the described dermatitis-treating bezoar medicine of claim 1, preferred weight (part) ratio range of preparation medicine of the present invention is: 0.5～1.2 part of Calculus Bovis, 50～55 parts of Herba Artemisiae Annuaes, 50～55 parts of Folium Pinis, 50～55 parts of Fructus Mumes, 50～60 parts of Herba Menthaes, 4.2～5.2 parts of Borneolum Syntheticums, 100～110 parts in glacial acetic acid.
3, the preparation method of dermatitis-treating bezoar medicine is characterized in that (weight is in gram), gets Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and is broken into coarse powder, ethanol with 80～85% is solvent, carry out percolation by 3ml/min speed, collect the about 700～900ml of percolate, add glacial acetic acid acid and shake up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
4,, it is characterized in that desirable 83% ethanol is that solvent carries out percolation according to the preparation method of the described dermatitis-treating bezoar medicine of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00126785 CN1360899A (en) | 2000-12-29 | 2000-12-29 | Dermatitis-treating bezoar medicine and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00126785 CN1360899A (en) | 2000-12-29 | 2000-12-29 | Dermatitis-treating bezoar medicine and its prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1360899A true CN1360899A (en) | 2002-07-31 |
Family
ID=4592068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00126785 Pending CN1360899A (en) | 2000-12-29 | 2000-12-29 | Dermatitis-treating bezoar medicine and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1360899A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
| US7666451B2 (en) | 2003-03-21 | 2010-02-23 | Elizabeth Anne Mazzio | Method of treating dyshidrosis(pompholyx) and related dry skin disorders |
-
2000
- 2000-12-29 CN CN 00126785 patent/CN1360899A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
| US7666451B2 (en) | 2003-03-21 | 2010-02-23 | Elizabeth Anne Mazzio | Method of treating dyshidrosis(pompholyx) and related dry skin disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446261B (en) | Chinese medicinal composition used for preventing and/or treating related skin lesion in tumour treatment | |
| CN103340965B (en) | External pharmaceutical composition used for treating skin diseases like eczema, dermatitis and tinea and preparation method thereof | |
| CN102805792A (en) | Ointment for treating hemorrhoids and preparation method thereof | |
| CN102940854B (en) | Traditional Chinese medicine composition for facilitating wound healing after surgical operations, preparation process and application | |
| CN107260612B (en) | Chloasma removing composition, application, compound preparation and preparation method | |
| CN1360899A (en) | Dermatitis-treating bezoar medicine and its prepn | |
| CN105125708B (en) | A kind of pharmaceutical composition and preparation method thereof for rhinitis | |
| CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
| CN104706919B (en) | A kind of pharmaceutical composition for the treatment of ulcer in body surface | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN101940652B (en) | Chinese medicinal liniment for treating psoriasis, multiple kinds of stubborn dermatitis and pruritus | |
| CN113813224A (en) | Novel azelaic acid gel and preparation method thereof | |
| CN106728168B (en) | A Chinese medicinal external preparation for treating eczema and psoriasis, and its preparation method | |
| CN100500173C (en) | Medicine for treating rheumatism and rheumatoid disease, and its preparation method | |
| CN104940304A (en) | Application for treating childhood asthma in remission phase through iontophoresis | |
| CN113144147B (en) | A topical Chinese medicinal composition for treating hypochondriac pain, and its preparation method | |
| CN105832657B (en) | A kind of compound lactic acid emulsifiable paste, preparation method and application | |
| CN109395050A (en) | Paediatrics external application massage the ointment formula, preparation method and application for treating diarrhea | |
| CN116832126B (en) | Chinese medicinal composition for relieving pain and preparation method thereof | |
| CN103735974B (en) | A kind of care drug of preventing the rear discomfort of operative incision healing | |
| CN107050393A (en) | Numbness of relaxing dispersing paste and preparation method and application | |
| CN107158093A (en) | A kind of external application hot compress preparation for treating lumbar vertebrae hyperosteogeny | |
| CN102406790A (en) | Traditional Chinese medicine capsule for treating hyperplasia of mammary glands and preparation method thereof | |
| CN106420467A (en) | Anti-allergic plant moisturizing composition and application thereof | |
| CN105833020A (en) | External-use nursing medicinal composition capable of promoting postoperative wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |